Drug Trial Radar · NCT04370379
Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients
Last checked: Nov 19, 2026Latest source record: Nov 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
May 28, 2020
Primary completion
Apr 30, 2021
Study completion May 8, 2021
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed for multi-center, open-label, randomized, dose escalation phase I trial to evaluate the safety and tolerability of a multiple dose intravitreal injection of IBI302 in neovascular AMD patients.
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
IBI302 (the first dose level)Drug
q4week (3 injections) followed by PRN dosing
IBI302 (the second dose level)Drug
q4week (3 injections) followed by PRN dosing
AfliberceptDrug
2mg, q4week (3 injections) followed by q8week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ocular safety, assessed by BCVA, slitlamp examination, ophthalmoscopy, IOP, fundus photographyTime frame: Baseline to Day140
- Incidence of adverse eventsTime frame: Baseline to Day140
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.